Skip to main content

Advertisement

Log in

In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors

  • PHARMACOKINETICS AND DISPOSITION
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective: The affinity of (+)-, (−)- and (±)-fluvastatin, a new synthetic HMG-CoA reductase inhibitor developed as a racemate, for specific human P450 monooxygenases in liver microsomes was compared with that of the pharmacologically active acidic forms of lovastatin, pravastatin and simvastatin.

Methods:

Affinity was determined as the inhibitory potency for prototype reactions for 3 major drug metabolising enzymes: diclofenac 4′-hydroxylation (CYP2C9), dextromethorphan O-demethylation (CYP2D6), and midazolam 1′-hydroxylation (CYP3A4).

Results:

Lovastatin acid, pravastatin and simvastatin acid displayed moderate affinity for all three P450 isozymes (estimated Ki > 50 μmol⋅l−1). Racemic and (+)- and (−)-fluvastatin showed moderate affinity (estimated Ki > 50 μmol⋅l−1) for CYP2D6 and CYP3A4, whereas their affinity for CYP2C9 was high (estimated Ki < 1 μmol⋅l−1). Diclofenac 4′-hydroxylation was competitively and stereoselectively inhibited, with measured Ki’s of 0.06 and 0.28 μmol⋅l−1 for (+)- and (−)-fluvastatin, respectively.

Conclusion:

Fluvastatin selectively inhibits a major drug metabolising enzyme (CYP2C9), the (+)-isomer (pharmacologically more active) showing 4–5 fold higher affinity. As already reported for lovastatin and simvastatin, in vivo drug interactions by inhibition of liver oxidation of CYP2C9 substrates (e.g. hypoglyceamic sulphonylureas and oral anticoagulants) may be expected.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 9 June 1995/Accepted in revised form: 7 November 1995

Rights and permissions

Reprints and permissions

About this article

Cite this article

Transon, C., Leemann, T. & Dayer, P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. E J Clin Pharmacol 50, 209–215 (1996). https://doi.org/10.1007/s002280050094

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002280050094

Navigation